Mavacoxib

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[1] It acts as a COX-2 inhibitor.[2]

Mavacoxib
Clinical data
Trade namesTrocoxil
AHFS/Drugs.comInternational Drug Names
ATCvet code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.248.948
Chemical and physical data
FormulaC16H11F4N3O2S
Molar mass385.34 g·mol−1
3D model (JSmol)
SMILES
  • C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F
InChI
  • InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
  • Key:TTZNQDOUNXBMJV-UHFFFAOYSA-N

Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]

References
  1. European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
  2. Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.
  3. Langreth R (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. St. Louis Section, American Chemical Society. 52 (5): 2. May 2001. Archived from the original (PDF) on 15 April 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.